Univariate analysis demonstrated that the PFS in ROS1‐positive NSCLC patients was significantly associated with treatment patterns (crizotinib vs chemotherapy, P < .001) (Table 3). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.